keyword
MENU ▼
Read by QxMD icon Read
search

Liposomal amphotericin b formulation

keyword
https://www.readbyqxmd.com/read/28928478/biomimetically-engineered-amphotericin-b-nano-aggregates-circumvent-toxicity-constraints-and-treat-systemic-fungal-infection-in-experimental-animals
#1
Qamar Zia, Owais Mohammad, Mohd Ahmar Rauf, Wasi Khan, Swaleha Zubair
Biomimetic synthesis of nanoparticles offers a convenient and bio friendly approach to fabricate complex structures with sub-nanometer precision from simple precursor components. In the present study, we have synthesized nanoparticles of Amphotericin B (AmB), a potent antifungal agent, using Aloe vera leaf extract. The synthesis of AmB nano-assemblies (AmB-NAs) was established employing spectro-photometric and electron microscopic studies, while their crystalline nature was established by X-ray diffraction...
September 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28925873/silver-nanoparticles-with-high-loading-capacity-of-amphotericin-b-characterization-bactericidal-and-antifungal-effects
#2
Victoria Leonhard, Roxana Valeria Alasino, Adrián Muñoz, Dante Miguel Beltramo
The purpose of this study was to evaluate the most appropriate conditions to generate silver nanoparticles (AgNPs) loaded with a potent antimycotic drug like amphotericin B (AmB), characterize the physicochemical properties, and also evaluate the cytotoxic effect and biological activity of these new nanostructures as a potential nanocarrier for hydrophobic drugs. It was determined that the optimal molar ratio between Ag and AmB is 1/1 given the uniformity of size around 1750 nm of the nanoparticles generated as well as their strongly negative ζ potential of -27 mV, a condition that favors repulsions between AgNPs and inhibiting their aggregation...
September 18, 2017: Current Drug Delivery
https://www.readbyqxmd.com/read/28874072/liposomal-formulations-in-the-pharmacological-treatment-of-leishmaniasis-a-review
#3
Vanessa Ortega, Selma Giorgio, Eneida de Paula
Conventional chemotherapy for leishmaniasis includes considerably toxic drugs and reports of drug-resistance are not uncommon. Liposomal encapsulated drugs appear as an option for the treatment of leishmaniasis, providing greater efficacy for the active and reducing its side effects by promoting superior tissue absorption, favoring drug penetration into the macrophages, and retarding its clearance from the site of action. In this paper, a review on the advances achieved with liposome-based anti-leishmaniasis drug delivery systems is presented...
September 5, 2017: Journal of Liposome Research
https://www.readbyqxmd.com/read/28865757/a-cell-impedance-based-real-time-in-vitro-assay-to-assess-the-toxicity-of-amphotericin-b-formulations
#4
Jean Menotti, Alexandre Alanio, Aude Sturny-Leclère, Sandrine Vitry, Félix Sauvage, Gillian Barratt, Stéphane Bretagne
Aerosolized liposomal amphotericin B (L-AmB) has been investigated as prophylaxis against invasive aspergillosis. However, the clinical results are controversial and some trials suggest that toxicity could be a limitation for wider use. Our aim was to assess the dynamics of cell toxicity induced in a human alveolar epithelial cell line (A549) after exposure to L-AmB (50 to 400μg/ml) or amphotericin B deoxycholate (D-AmB; 50 to 200μg/ml) by monitoring real-time A549 cell viability using an impedance-based technology...
September 1, 2017: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/28815733/comparison-of-the-pharmacokinetic-profiles-of-two-different-amphotericin-b-formulations-in-healthy-dogs
#5
B Bingöl, T Bakirel
This study was conducted to compare the pharmacokinetic profiles of conventional (Fungizone(®) ) and liposomal amphotericin B (AmBisome(®) ) formulations in order to predict their therapeutic properties, and evaluate their potential differences in veterinary treatment. For this purpose, twelve healthy mixed breed dogs received both drugs at a dose of 0.6 mg/kg by intravenous infusion over a 4-min period in a total volume of 40 ml. Blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72 and 96 hr after dosing, and concentrations of drug in plasma were determined by high-performance liquid chromatography (HPLC)...
August 16, 2017: Journal of Veterinary Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28815602/efficacy-and-safety-of-amphotericin-b-formulations-a-network-meta-analysis-and-a-multicriteria-decision-analysis
#6
Fernanda S Tonin, Laiza M Steimbach, Helena H Borba, Andreia C Sanches, Astrid Wiens, Roberto Pontarolo, Fernando Fernandez-Llimos
OBJECTIVES: Despite its broad spectrum, conventional amphotericin B (AB) is associated with serious adverse events. Lipid-based formulations may offer safer options. We aimed to synthesize the evidence of efficacy and safety of AB formulations. METHODS: We performed a systematic review and network meta-analysis (NMA) to compare all available formulations: conventional AB; lipid complex or ABLC; colloidal dispersion or ABCD; liposomal or LAB; AB in Intralipid. Randomized controlled trials were searched in four databases...
August 17, 2017: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/28805117/fungal-fatal-attraction-a-mechanistic-review-on-targeting-liposomal-amphotericin-b-ambisome-%C3%A2-to-the-fungal-membrane
#7
Linda Soo Hoo
Liposomal amphotericin B (AmBisome(®)) is a lipid-based nanotherapeutic that is used successfully worldwide to treat a broad range of life-threatening invasive fungal infections. In subtropical regions, AmBisome is emerging as the treatment of choice for human parasitic protozoan pathogens such as those from the genus Leishmania. The key to the remarkable efficacy of AmBisome is attributed to its liposome based formulation to deliver a potent drug at high dosage with significantly reduced toxicity in patients with immunocompromised systems...
August 14, 2017: Journal of Liposome Research
https://www.readbyqxmd.com/read/28756612/clinical-pharmacokinetics-of-systemically-administered-antileishmanial-drugs
#8
REVIEW
Anke E Kip, Jan H M Schellens, Jos H Beijnen, Thomas P C Dorlo
This review describes the pharmacokinetic properties of the systemically administered antileishmanial drugs pentavalent antimony, paromomycin, pentamidine, miltefosine and amphotericin B (AMB), including their absorption, distribution, metabolism and excretion and potential drug-drug interactions. This overview provides an understanding of their clinical pharmacokinetics, which could assist in rationalising and optimising treatment regimens, especially in combining multiple antileishmanial drugs in an attempt to increase efficacy and shorten treatment duration...
July 29, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28656554/fluconazole-non-susceptible-cryptococcus-neoformans-relapsing-refractory-cryptococcosis-and-long-term-use-of-liposomal-amphotericin-b-in-an-aids-patient
#9
Rodrigo de Carvalho Santana, Letícia Aparecida Schiave, Alda Soares Dos Santos Quaglio, Cristiane Masetto de Gaitani, Roberto Martinez
The treatment of cryptococcosis is hampered by inefficacy or intolerance to the recommended antifungal agents. A patient diagnosed with AIDS had multiple relapses of cryptococcal infection, which became refractory to antifungal agents during the course of therapy. During the follow-up, the patient developed renal toxicity due to amphotericin B use and non-susceptibility of isolated Cryptococcus neoformans to fluconazole was detected. Thereafter, antifungal treatment was performed exclusively with liposomal amphotericin B, reaching a cumulative dose of 19,180 mg over 46 months...
June 27, 2017: Mycopathologia
https://www.readbyqxmd.com/read/28622334/sterol-14%C3%AE-demethylase-mutation-leads-to-amphotericin-b-resistance-in-leishmania-mexicana
#10
Roy Mwenechanya, Julie Kovářová, Nicholas J Dickens, Manikhandan Mudaliar, Pawel Herzyk, Isabel M Vincent, Stefan K Weidt, Karl E Burgess, Richard J S Burchmore, Andrew W Pountain, Terry K Smith, Darren J Creek, Dong-Hyun Kim, Galina I Lepesheva, Michael P Barrett
Amphotericin B has emerged as the therapy of choice for use against the leishmaniases. Administration of the drug in its liposomal formulation as a single injection is being promoted in a campaign to bring the leishmaniases under control. Understanding the risks and mechanisms of resistance is therefore of great importance. Here we select amphotericin B-resistant Leishmania mexicana parasites with relative ease. Metabolomic analysis demonstrated that ergosterol, the sterol known to bind the drug, is prevalent in wild-type cells, but diminished in the resistant line, where alternative sterols become prevalent...
June 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28490252/visceral-leishamiosis-in-immunocompromised-host-an-update-and-literature-review
#11
Pasquale Pagliano, Silvano Esposito
Visceral leishmaniasis (VL) is a chronic infectious disease endemic in tropical and sub-tropical areas including the Mediterranean basin, caused by a group of protozoan parasites of the genus Leishmania and transmitted by phlebotomine sandflies. Immunocompromised patients, in particular HIV positive, are considered at risk of VL. They report atypical signs and poor response to treatment due to impairment of T-helper and regulatory cells activity. Laboratory diagnosis is based on microscopy on bone marrow or spleen aspirates...
May 10, 2017: Journal of Chemotherapy
https://www.readbyqxmd.com/read/28480760/tissue-pharmacokinetics-and-pharmacodynamics-of-ambisome%C3%A2-l-ambis-in-uninfected-and-infected-animals-and-their-effects-on-dosing-regimens
#12
J P Adler-Moore, R T Proffitt, J A Olson, G M Jensen
By selecting a unique combination of lipids and amphotericin B, the liposome composition for AmBisome® (L-AmBis) has been optimized resulting in a formulation that is minimally toxic, targets to fungal cell walls, and distributes into and remains for days to weeks in various host tissues at drug levels above the MIC for many fungi. Procedures have been standardized to ensure that large scale production of the drug retains the drug's low toxicity profile, favorable pharmacokinetics and antifungal efficacy. Tissue accumulation and clearance with single or multiple intravenous administration is similar in uninfected and infected animal species, with tissue accumulation being dose-dependent and the liver and spleen retaining the most drug...
May 31, 2017: Journal of Liposome Research
https://www.readbyqxmd.com/read/28420334/mucormycosis-in-renal-transplant-recipients-review-of-174-reported-cases
#13
Yan Song, Jianjun Qiao, Gaffi Giovanni, Guangjun Liu, Hao Yang, Jianyong Wu, Jianghua Chen
BACKGROUND: Mucormycosis is a highly lethal fungal infection especially in immunocompromised individuals. METHODS: In order to review the epidemiology, diagnosis, and treatment of mucormycosis in renal transplant recipients we searched publications of mucormycosis cases in renal transplant recipients in PUBMED database up to December 2015. RESULTS: A total of 174 cases in renal transplant recipients were included in this review. Most of the cases (76%) were male...
April 18, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28339539/unique-aggregation-of-conjugated-amphotericin-b-and-its-interaction-with-lipid-membranes
#14
Sarah Kagan, Diana E Ickowicz, Abraham J Domb, Arie Dagan, Itzhack Polacheck
The purpose of this paper was to investigate the aggregation of amphotericin B (AMB) and AMB-arabinogalactan conjugate (AMB-AGC), and the interactions of these drugs with free and membrane-embedded sterols. Aggregation of AMB and AMB-AGC was studied by circular dichroic (CD) and UV absorbance spectroscopic techniques. The effect of liposomes on the spectra was utilized to investigate the interactions of aggregates with membrane-embedded sterols. Interaction with free sterols was studied by measuring sterols' effect on AMB/AMB-AGC susceptibility test...
June 1, 2017: Medical Mycology: Official Publication of the International Society for Human and Animal Mycology
https://www.readbyqxmd.com/read/28216467/nmr-and-esr-study-of-amphotericin-b-interactions-with-various-binary-phosphatidylcholine-phosphatidylglycerol-membranes
#15
J C Debouzy, L Mehenni, D Crouzier, M Lahiani-Skiba, G Nugue, M Skiba
Several biologically relevant phospholipids are considered as potential excipients for IV administration liposome's formulation of AMB (Biopharmaceututics Classification System Class IV). On the basis of in vivo bioavaibility studies, DMPC and DMPG were ranked as the first potent encapsulation enhancers for this model drug, especially if one expects to target DMPG rich systems as pulmonary surfactant. Subsequently, dispersions (multilayers) of DMPC, DMPG or in binary systems with various molar ratios were prepared with or without AMB (molar ratios AMB/lipid) and further investigated using the (1)H-,(31)P-NMR methods...
April 15, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28216150/novel-biodegradable-poly-gamma-glutamic-acid-amphotericin-b-complexes-show-promise-as-improved-amphotericin-b-formulations
#16
Tan Dinh, Qamar Zia, Swaleha Zubair, Paul Stapleton, Ruchi Singh, Mohammad Owais, Satyanarayana Somavarapu
Commercially available amphotericin B (AmB) formulations are limited by cytotoxicities, lower efficacies, shelf-life related issues and high production costs. In this study, AmB complexes based on poly(gamma-glutamic acid) (PGGA) were prepared and evaluated for their efficacies against AmB-deoxycholate (Fungizone(®)) and liposomal AmB (AmBisome(®)). Physical characterizations showed that AmB/PGGA complexes are nanoscopic (20-40 nm) with a negative zeta potential (-45.5 to -51.0 mV), water-soluble, stable in solution (up to 4 weeks, at 4 °C and 25 °C), and have a high drug loading (up to 35% w/w)...
February 16, 2017: Nanomedicine: Nanotechnology, Biology, and Medicine
https://www.readbyqxmd.com/read/28191796/the-cost-of-treating-mucormycosis-with-isavuconazole-compared-with-standard-therapy-in-the-uk
#17
Emma Bagshaw, Daniel Kuessner, Jan Posthumus, Cesar Escrig, Michael Blackney, Sebastian Marcel Heimann, Oliver Andreas Cornely
AIM: Mucormycosis is a fungal infection associated with high mortality. Until recently, the only licensed treatments were amphotericin B (AMB) formulations. Isavuconazole (ISAV) is a new mucormycosis treatment. A UK-based economic model explored treatment costs with ISAV versus liposomal AMB followed by posaconazole. MATERIALS & METHODS: As a matched case-control analysis showed similar efficacy for ISAV and AMB, a cost-minimization approach was taken. Direct costs - drug acquisition, monitoring and administration, and hospitalization costs - were estimated from the National Health Service perspective...
February 13, 2017: Future Microbiology
https://www.readbyqxmd.com/read/28097002/ambisome-induced-avascular-necrosis-of-the-alae-of-the-nose-of-a-very-young-girl-suffering-from-kala-azar-a-case-report
#18
Shomik Maruf, Proggananda Nath, Fatima Aktar, Ariful Basher
Although liposomal amphotericin B (AmBisome) is considered as the first-line treatment for New Kala-azar, there is not enough evidence on the dosage formulation in children and its effect on them. Being considered as the safest drug for treatment of Kala-azar, this case of AmBisome-induced avascular necrosis now gives rise to the question; whether it is actually safe enough and if a dosage modification is needed in case of children. This so far, to the best of our knowledge, is the first instance of such severe adverse event due to AmBisome administration...
December 2016: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28011960/visceral-leishmaniasis-in-immunocompromised-diagnostic-and-therapeutic-approach-and-evaluation-of-the-recently-released-idsa-guidelines
#19
Pasquale Pagliano, Tiziana Ascione, Giusy Di Flumeri, Giovanni Boccia, Francesco De Caro
Visceral Leishmaniasis (VL) is a chronic infectious disease endemic in tropical and sub-tropical areas including the Mediterranean basin, caused by a group of protozoan parasites of the genus Leishmania and transmitted by phlebotomine sandflies. Typically, VL is classified as a zoonotic infection when Leishmania infantum is the causative agent and as an anthroponotic one when L. donovani is the causative agent. Immunocompromised patients, in particular HIV positive, are considered at risk of VL. They may present atypical signs and poor response to the treatment due to a compromission of T-helper and regulatory cells activity...
December 1, 2016: Le Infezioni in Medicina
https://www.readbyqxmd.com/read/27878878/efficacy-and-safety-of-amphotericin-b-lipid-based-formulations-a-systematic-review-and-meta-analysis
#20
REVIEW
Laiza M Steimbach, Fernanda S Tonin, Suzane Virtuoso, Helena H L Borba, Andréia C C Sanches, Astrid Wiens, Fernando Fernandez-Llimós, Roberto Pontarolo
Invasive fungal infections, an important cause of mortality, are primarily treated using amphotericin B, which is available in different formulations, both conventional and lipid-based (liposomal, lipid complex, colloidal dispersion and Intralipid(®) infusion). The aim of our study was to determine the efficacy and safety of conventional amphotericin B vs its lipid-based formulations. A systematic review followed by pairwise meta-analysis was performed, including randomised controlled trials (RCTs) that evaluated the use of lipid-based amphotericin B in patients with any degree of immunosuppression and susceptibility to invasive fungal infection...
March 2017: Mycoses
keyword
keyword
101730
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"